Raloxifene hydrochloride administration is via the oral route. Raloxifene hydrochloride is available as 60 mg tablets.

- Indications for the drug are the treatment and prevention of postmenopausal osteoporosis. The recommended dose for osteoporosis is 60 mg by mouth daily.

- It is also prescribed for prevention and risk reduction of invasive breast cancer in postmenopausal women demonstrating a high risk for invasive breast cancer.

- Clinical trials had reported some beneficial effects of raloxifene during menopause, decreasing LDL levels and reducing the risk of pelvic organ prolapse and breast cancer. No reports exist of an effect on cognitive mood or sleep disturbances.

**Special Population**

**Patients with Renal Impairment:**Use with caution; safety and efficacy are not well known in patients with moderate or severe renal impairment.

**Patients with Liver Impairment:**Safety and efficacy are not well known in patients with hepatic impairment.

**Pregnancy and Breastfeeding Implications:**Raloxifene is a US FDA pregnancy category X medicine. Pregnancy and lactation constitute a contraindication to using raloxifene. Fertile women wishing to become pregnant need to avoid or discontinue this drug.Â It is not known whether raloxifene is excreted in human milk. Many medicines are excreted in human milk, so exercise caution when administered to a nursing woman.